The ADC binds EGFR/HER3 on tumor cells, is internalized, and releases the topoisomerase I–inhibiting payload (brengitecan) to induce DNA damage and cell death; DNA topoisomerase I is the intracellular enzyme inhibited, not the antigen targeted by the antibody.